Tsoutsou Pelagia G, Zaman Khalil, Martin Lluesma Silvia, Cagnon Laurene, Kandalaft Lana, Vozenin Marie-Catherine
Division of Oncology, Radio-oncology Department, Vaudois University Hospital Centre (CHUV), Lausanne, Switzerland.
Radio-Oncology Research Laboratory, Vaudois University Hospital Centre (CHUV), Epalinges, Switzerland.
Front Oncol. 2018 Dec 12;8:609. doi: 10.3389/fonc.2018.00609. eCollection 2018.
The association of radiotherapy and immunotherapy has recently emerged as an exciting combination that might improve outcomes in many solid tumor settings. In the context of breast cancer, this opportunity is promising and under investigation. Given the heterogeneity of breast cancer, it might be meaningful to study the association of radiotherapy and immunotherapy distinctly among the various breast cancer subtypes. The use of biomarkers, such as tumor infiltrating lymphocytes, which are also associated to breast cancer heterogeneity, might provide an opportunity for tailored studies. This review highlights current knowledge of the association of radiotherapy and immunotherapy in the setting of breast cancer and attempts to highlight the therapeutic opportunities among breast cancer heterogeneity.
放射治疗与免疫治疗的联合最近已成为一种令人兴奋的组合，可能会改善许多实体瘤情况下的治疗结果。在乳腺癌的背景下，这一机会很有前景且正在研究中。鉴于乳腺癌的异质性，在不同的乳腺癌亚型中分别研究放射治疗与免疫治疗的联合可能具有重要意义。使用生物标志物，如肿瘤浸润淋巴细胞，其也与乳腺癌异质性相关，可能为针对性研究提供机会。本综述强调了目前关于乳腺癌背景下放射治疗与免疫治疗联合的知识，并试图突出乳腺癌异质性中的治疗机会。
